Zeto New Wave EEG System Wins FDA Clearance For At-Home Brain Monitoring

Key Takeaways

• FDA 510(k) clearance adds third approved Zeto EEG platform
• Gel‑free 21‑electrode headset enables 2.5‑hour at‑home recordings
• Integrated cloud and AI tools support remote seizure detection
• Simplified setup addresses EEG technologist shortages in clinics
• Multimodal video, ECG, EOG capture expands diagnostic capabilities

Pulse Analysis

The FDA’s 510(k) clearance of Zeto’s New Wave system marks a pivotal moment for at‑home neuro‑diagnostics, a segment that has struggled with regulatory hurdles and limited device options. As hospitals and outpatient centers grapple with mounting demand for EEG studies, the ability to deploy a compact, gel‑free headset without extensive technician training offers a clear competitive edge. Zeto’s track record—now three cleared platforms—signals to investors and clinicians that the company can navigate the stringent approval process while delivering clinically viable technology.

New Wave’s design focuses on usability and flexibility. The 21‑electrode, soft‑tip array follows the standard 10‑20 layout, eliminating messy gel applications and cutting prep time to minutes. Coupled with a lightweight recording unit and a cloud‑based portal, clinicians can initiate studies in a primary‑care office or a patient’s living room and review data remotely. The multimodal capability—synchronizing video, audio, ECG, EOG and EMG—provides a richer diagnostic picture, supporting not only epilepsy monitoring but also broader neurological assessments such as sleep disorders and traumatic brain injury.

Beyond the device itself, Zeto’s integration of AI‑driven seizure detection and quantitative EEG analytics aligns with a broader industry shift toward data‑centric care. Remote access and automated interpretation reduce bottlenecks, allowing neurologists to focus on treatment decisions rather than data collection. As reimbursement models evolve to reward outcomes and telehealth, platforms like New Wave are well‑positioned to capture market share from legacy EEG manufacturers still reliant on bulky, technician‑heavy systems. The clearance therefore not only expands Zeto’s product suite but also accelerates the adoption of scalable, AI‑enhanced neuro‑monitoring across the United States.